Physician profile
Anne E Winkler
NPI 1346307220
$1,628,102.65
in general payments reported to CMS, 2019-2025
23 companies · $229K in 2025
The $229K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428K · 2020: $147K · 2021: $175K · 2022: $245K · 2023: $193K · 2024: $211K · 2025: $229K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $466K · Travel and Lodging: $88K · Consulting Fee: $62K · Food and Beverage: $17K · Education: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $465,644.75 |
| Travel and Lodging | $87,676.55 |
| Consulting Fee | $61,980.00 |
| Food and Beverage | $17,223.03 |
| Education | $726.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $476,810.92 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $159,231.03 | 2022-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals Lp | $127,480.00 | 2020-2025 | Saphnelo, Evusheld |
| Lilly USA, LLC | $113,406.32 | 2019-2025 | Taltz, Zepbound |
| Amgen INC. | $99,395.50 | 2019-2025 | Otezla, Otezla, Tavneos |
| Aurinia Pharma U.S., INC. | $98,568.37 | 2021-2023 | Lupkynis |
| Janssen Biotech, INC. | $94,756.55 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $84,410.04 | 2019-2025 | |
| Genzyme Corporation | $83,205.91 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $80,223.94 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $67,611.72 | 2019-2024 | |
| Glaxosmithkline, LLC. | $57,384.81 | 2019-2025 | Benlysta, Nucala |
| Celgene Corporation | $36,228.97 | 2019 | |
| Eli Lilly and Company | $17,291.33 | 2022-2023 | Taltz |
| Regeneron Healthcare Solutions, INC. | $16,601.11 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $14,696.08 | 2019-2023 | Actemra, Rituxan |
| Sanofi-Aventis U.S. LLC | $363.97 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $230.87 | 2019-2025 | Orencia |
| Genentech, INC. | $77.47 | 2022-2023 | Actemra |
| Radius Health, INC. | $60.50 | 2019-2024 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.68 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $17.64 | 2019 | |
| Horizon Therapeutics Plc | $14.92 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Winkler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.